Studies in mouse models of breast and pancreatic cancer showed that losartan reduces intratumoral expression of thrombospondin-1 (THBS-1), an activator of transforming growth factor beta (TGF-β), resulting in a significant decrease in intratumoral collagen and hyaluronan. The gene discussed is THBS1; the disease is pancreatic neoplasm.